You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest A1c Test Articles
Popular A1c Test Articles
Highly Recommended A1c Test Articles
Send a link to this page to your friends and colleagues.
An experimental exenatide (Byetta)-like drug called liraglutide has shown the ability to enhance insulin and glucagon production and suppress appetite in type 2 patients, according to a report in the British medical journal The Lancet.
Liraglutide is a manmade analog of the hormone GLP-1 (glucagon-like peptide-1), which stimulates the growth of insulin-producing beta cells in the pancreas and insulin secretion.
Because of liraglutide's success in the phase 3 trial, its manufacturer, Novo Nordisk, will now seek approval from the Food and Drug Administration to market liraglutide in the United States.
In the one-year Novo Nordisk-funded study conducted by the Baylor College of Medicine in Houston, 746 type 2 patients received once daily injections of either 1.2 mg or 1.8 mg of liraglutide or a once daily oral tablet of glimepiride, a sulfonylurea that promotes insulin production.
Patients receiving liraglutide also took dummy pills, while patients taking glimepiride also received dummy injections.
As they began treatment, patients' A1c's ranged from 7% to 11%. By the end of the study:
Six patients had to drop out of the study due to severe nausea. Common side effect of exenatide-like drugs are. nausea, diarrhea, and vomiting, symptoms that ease up or disappear within 30 days in most patients.
The study also tracked weight: in the first 16 weeks, the subjects taking liraglutide lost weight, while most of those taking glimepiride gained weight.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.